MENU
RIGL
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Rigel Pharmaceuticals (RIGL) Ownership - Who owns Rigel Pharmaceuticals?
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
611 Gateway Boulevard
Phone
+1 650 624-1100
Employees
147
Web
https://www.rigel.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
741.53M
P/E Ratio
7.39
Total Cash
108.38M
Projected Growth
N/A
Total Debt
61.04M
Revenue
267.92M
Risk (Beta)
0.75
Dividend Yield
N/A
Total Cash/Share
6.04
Total Debt/Equity
N/A
Revenue/Share
14.88 USD as % of share price
Fundamentals
RIGL
Capitalization
742M
P/E Ratio
7.39
Risk (Beta)
0.75
Dividend Yield
N/A
Total Cash
108M
Total Cash/Share
6.04
Total Debt
61M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
14.88%
Revenue
268M
ROE
N/A
Book Value
81.9M
P/B Ratio
8.79
Cash Flow
N/A
Earnings
5.5
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
18K
Current Ratio
2.02
Current Revenue Per Employee
620030.50
Dividends Per Share - Security
N/A
EBITDA
109M
Float
N/A
Float - Current
N/A
Gross Income Margin
95.57
Revenue To Assets
58.38
Shares Held By Institutions
357M
Shares Outstanding - Current
17.9M
Total Liabilities
125M
Total Volume MTD
N/A
Value
N/A
Gain YTD
145.779
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information
General Information
a clinical-stage drug development company that discovers and develops novel, small-molecule drugs
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
611 Gateway Boulevard
Phone
+1 650 624-1100
Employees
147
Web
https://www.rigel.com